Persistence of antidepressant treatment for depressive disorder in Taiwan

General Hospital Psychiatry

Volumn 35, Issue 3, 2013, Pages 279-285

  Wu, Chi Shin ^a,b,c   Shau, Wen Yi ^d   Chan, Hung Yu ^c,e,f   Lai, Mei Shu ^b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d Center for Drug Evaluation   (Taiwan)

^e Taoyuan Mental Hospital   (Taiwan)

^f CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

Antidepressant; Combination; Discontinuation; Persistence; Switching

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUPENTIXOL; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MELITRACEN; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GROUPS BY AGE; HEALTH INSURANCE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SLEEP DISORDER; TAIWAN;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; COHORT STUDIES; DEPRESSIVE DISORDER; DRUG SUBSTITUTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; TAIWAN; YOUNG ADULT;

EID: 84876952531     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2012.12.003     Document Type: Article

References (44)

1. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
2. WHO The global burden of disease: 2004 update Geneva: World Health Organization http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html.
3. American Psychiatric Association practice guideline for the treatment of patients with major depressive disorder http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx.
4. Olfson M., Marcus S.C., Tedeschi M., Wan G.J. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006, 163:101-108.
5. Melfi C.A., Chawla A.J., Croghan T.W., Hanna M.P., Kennedy S., Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998, 55:1128-1132.
6. Nantz E., Liu-Seifert H., Skljarevski V. Predictors of premature discontinuation of treatment in multiple disease states. Patient Prefer Adherence 2009, 3:31-43.
7. Montgomery S.A., Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 1995, 9(Suppl 4):33-40.
8. Barbui C., Hotopf M., Freemantle N., Boynton J., Churchill R., Eccles M.P., et al. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev 2000, CD002791.
9. Cipriani A., Furukawa T.A., Salanti G., Geddes J.R., Higgins J.P., Churchill R., et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373:746-758.
10. Andrade S.E., Walker A.M., Gottlieb L.K., Hollenberg N.K., Testa M.A., Saperia G.M., et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings?. N Engl J Med 1995, 332:1125-1131.
11. Crown W.H., Treglia M., Meneades L., White A. Long-term costs of treatment for depression: impact of drug selection and guideline adherence. Value Health 2001, 4:295-307.
12. Wu E., Greenberg P., Yang E., Yu A., Ben-Hamadi R., Erder M.H. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants. Curr Med Res Opin 2008, 24:2805-2813.
13. Robinson R.L., Long S.R., Chang S., Able S., Baser O., Obenchain R.L., et al. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. J Manag Care Pharm 2006, 12:43-54.
14. Sheehan D.V., Keene M.S., Eaddy M., Krulewicz S., Kraus J.E., Carpenter D.J. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008, 22:963-973.
15. Mullins C.D., Shaya F.T., Meng F., Wang J., Harrison D. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 2005, 25:660-667.
16. Serna M.C., Cruz I., Real J., Gasco E., Galvan L. Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry 2010, 25:206-213.
17. Milea D., Guelfucci F., Bent-Ennakhil N., Toumi M., Auray J.-P. Antidepressant monotherapy: a claims database analysis of treatment changes and treatment duration. Clin Ther 2010, 32:2057-2072.
18. Ereshefsky L., Saragoussi D., Despiegel N., Hansen K., Francois C., Maman K. The 6-month persistence on SSRIs and associated economic burden. J Med Econ 2010, 13:527-536.
19. Sawada N., Uchida H., Suzuki T., Watanabe K., Kikuchi T., Handa T., et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry 2009, 9:38.
20. Liu X., Chen Y., Faries D.E. Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder. Clin Econ Outcomes Res: CEOR 2011, 3:63-72.
21. Beland S.G., Tournier M., Galbaud du Fort G., Crott R., Ducruet T., Pariente A., et al. Economic impact of nonpersistence with antidepressant treatment in the adult population of Quebec: a comparative cost-effectiveness approach. Value Health 2011, 14:492-498.
22. Goethe J.W., Woolley S.B., Cardoni A.A., Woznicki B.A., Piez D.A. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J Clin Psychopharmacol 2007, 27:451-458.
23. van Geffen E.C., van Hulten R., Bouvy M.L., Egberts A.C., Heerdink E.R. Characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor treatment. Ann Pharmacother 2008, 42:218-225.
24. Sihvo S., Isometsa E., Kiviruusu O., Hamalainen J., Suvisaari J., Perala J., et al. Antidepressant utilisation patterns and determinants of short-term and non-psychiatric use in the Finnish general adult population. J Affect Disord 2008, 110:94-105.
25. Cheng T.M. Taiwan's new national health insurance program: genesis and experience so far. Health Aff 2003, 22:61-76.
26. Wu C.S., Shau W.Y., Chan H.Y., Lee Y.C., Lai Y.J., Lai M.S. Utilization of antidepressants in Taiwan: a nationwide population-based survey from 2000 to 2009. Pharmacoepidemiol Drug Saf 2012, 21:980-988.
27. Bureau of National Health Insurance, Department of Health, Executive Yuan http://www.nhi.gov.tw/English/index.aspx.
28. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487-497.
29. Gardarsdottir H., Heerdink E.R., van Dijk L., Egberts A.C. Indications for antidepressant drug prescribing in general practice in the Netherlands. J Affect Disord 2007, 98:109-115.
30. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
31. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
32. Guidelines for ATC classification and DDD assignment 2009, WHO Collaborating Centre for Drug Statistic Methodology, WHO, Oslo. http://www.whocc.no/filearchive/publications/2010guidelines.pdf.
33. Andersen P.K., Abildstrom S.Z., Rosthoj S. Competing risks as a multi-state model. Stat Methods Med Res 2002, 11:203-215.
34. Rosthoj S., Andersen P.K., Abildstrom S.Z. SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Programs Biomed 2004, 74:69-75.
35. Liao S.C., Chen W.J., Lee M.B., Lung F.W., Lai T.J., Liu C.Y., et al. Low prevalence of major depressive disorder in Taiwanese adults: possible explanations and implications. Psychol Med 2011, 1-11.
36. Sihvo S., Wahlbeck K., McCallum A., Sevon T., Arffman M., Haukka J., et al. Increase in the duration of antidepressant treatment from 1994 to 2003: a nationwide population-based study from Finland. Pharmacoepidemiol Drug Saf 2010, 19:1186-1193.
37. Mojtabai R., Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 2010, 67:26-36.
38. Dodd S., Horgan D., Malhi G.S., Berk M. To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 2005, 89:1-11.
39. Rocha F.L., Fuzikawa C., Riera R., Hara C. Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol 2012, 32:278-281.
40. Bull S.A., Hu X.H., Hunkeler E.M., Lee J.Y., Ming E.E., Markson L.E., et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002, 288:1403-1409.
41. Pfeiffer P.N., Ganoczy D., Zivin K., Valenstein M. Benzodiazepines and adequacy of initial antidepressant treatment for depression. J Clin Psychopharmacol 2011, 31:360-364.
42. Stahl S.M., Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 2008, 13:855-870.
43. Machado M., Einarson T.R. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. J Clin Pharm Ther 2010, 35:177-188.
44. Chou Y.J., Yip W.C., Lee C.H., Huang N., Sun Y.P., Chang H.J. Impact of separating drug prescribing and dispensing on provider behaviour: Taiwan's experience. Health Policy Plan 2003, 18:316-329.